Here are three things to know.
1. The FDA previously approved Imbruvica for the treatment of lymphocytic leukemia.
2. Under the expanded approval, the drug can be used to treat adult patients with chronic graft versus host disease, which occurs when immune cells from donated tissues — often stem cells from donated bone marrow — attack the new host’s body cells.
3. Imbruvica is the first FDA-approved therapy for the treatment of chronic graft versus host disease.
More articles on supply chain:
Senate passes FDA user fee reauthorization bill
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
